Innate immunity against HIV: A priority target for HIV prevention research

Retrovirology

Volumn 7, Issue , 2010, Pages

  Borrow, Persephone ^a   Shattock, Robin J ^b   Vyakarnam, Annapurna ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERFERON; MICROBICIDE; ANTIINFECTIVE AGENT;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DENDRITIC CELL; DRUG DESIGN; DRUG TARGETING; EUROPEAN UNION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFECTION PREVENTION; INNATE IMMUNITY; MACROPHAGE FUNCTION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; RESEARCH PRIORITY; REVIEW; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; ANIMAL; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; ANTI-INFECTIVE AGENTS; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE;

EID: 77957673112     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-84     Document Type: Review

References (123)

1. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K, . Group. BVE Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671. 10.1086/508748, 17109337, Group. BVE.
2. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 2008, 205:7-12. 10.1084/jem.20072681, 2234358, 18195078.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220. 10.1056/NEJMoa0908492, 19843557.
4. Rhee EG, Barouch DH. Harnessing innate immunity for HIV vaccine development. Clin Exp Immunol 2009, 157:174-180. 10.1111/j.1365-2249.2009.03928.x, 2730842, 19604256.
5. Harandi AM, Medaglini D, Shattock RJ, . EUROPRISE. WGcb Vaccine adjuvants: a priority for vaccine research. Vaccine 2010, 28:2363-2366. 10.1016/j.vaccine.2009.12.084, 20064476, EUROPRISE. WGcb.
6. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008, 105:7552-7557. 10.1073/pnas.0802203105, 2387184, 18490657.
7. Münch J, Rücker E, Ständker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007, 131:1059-1071. 10.1016/j.cell.2007.10.014, 18083097.
8. Roan NR, Münch J, Arhel N, Mothes W, Neidleman J, Kobayashi A, Smith-McCune K, Kirchhoff F, Greene WC. The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol 2009, 83:73-80. 10.1128/JVI.01366-08, 2612336, 18945786.
9. Kim KA, Yolamanova M, Zirafi O, Roan NR, Staendker L, Forssmann WG, Burgener A, Dejucq-Rainsford N, Hahn BH, Shaw GM, et al. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology 2010, 7:55. 10.1186/1742-4690-7-55, 2914040, 20573198.
10. Nakashima H, Yamamoto N, Masuda M, Fuji I. Defensins inhibit HIV replication in vitro. AIDS 1993, 7:1129. 10.1097/00002030-199308000-00019, 8397954.
11. Quiñones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003, 17:F39-48. 10.1097/00002030-200311070-00001, 14571200.
12. Guo CJ, Tan N, Song L, Douglas SD, Ho WZ. Alpha-defensins inhibit HIV infection of macrophages through upregulation of CC-chemokines. AIDS 2004, 18. 10.1097/00002030-200405210-00020, 15166542.
13. Chang TL, Vargas JJ, DelPortillo A, Klotman ME. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 2005, 115:765-773. 548697, 15719067.
14. Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Terra Maggiore GM, Berrone S, Kleinman C, Wu Z, Abdelwahab S, et al. Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol 2005, 79:14318-14329. 10.1128/JVI.79.22.14318-14329.2005, 1280242, 16254366.
15. Gallo SA, Wang W, Rawat SS, Jung G, Waring AJ, Cole AM, Lu H, Yan X, Daly NL, Craik DJ, et al. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 2006, 281:18787-18792. 10.1074/jbc.M602422200, 16648135.
16. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P. Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 2007, 109:2928-2935.
17. Klotman ME, Rapista A, Teleshova N, Micsenyi A, Jarvis GA, Lu W, Porter E, Chang TL. Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. J Immunol 2008, 180:6176-6185.
18. Territo MCGT, Selsted ME, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989, 84:2017-2020. 10.1172/JCI114394, 304087, 2592571.
19. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schröder JM, Wang JM, Howard OM, Oppenheim JJ. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286:525-528. 10.1126/science.286.5439.525, 10521347.
20. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000, 68:9-14.
21. Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, Weinberg A, Sieg SF. Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 2007, 104:18631-18635. 10.1073/pnas.0702130104, 2141828, 18006661.
22. Shi J, Aono S, Lu W, Ouellette AJ, Hu X, Ji Y, Wang L, Lenz S, van Ginkel FW, Liles M, et al. A novel role for defensins in intestinal homeostasis: regulation of IL-1beta secretion. J Immunol 2007, 179:237-243.
23. Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, MacDonald KS, Broliden K, Hirbod T, Group KHS. Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS 2009, 23:309-317. 10.1097/QAD.0b013e328321809c, 19114868.
24. Consortium CSaA Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 2005, 437:69-87. 10.1038/nature04072, 16136131, Consortium CSaA.
25. Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachihi C, Pak BJ, Podust VN, Broliden K, Hirbod T, et al. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009, 23:1669-1677. 10.1097/QAD.0b013e32832ea643, 19553806.
26. Jana NK, Gray LR, Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J Virol 2005, 79:6432-6440. 10.1128/JVI.79.10.6432-6440.2005, 1091668, 15858026.
27. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 2004, 200:1337-1346. 10.1084/jem.20041115, 2211913, 15545357.
28. Py B, Basmaciogullari S, Bouchet J, Zarka M, Moura IC, Benhamou M, Monteiro RC, Hocini H, Madrid R, Benichou S. The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS ONE 2009, 4:e5006. 10.1371/journal.pone.0005006, 2659420, 19333378.
29. Alvarez R, Reading J, King DFL, Hayes M, Easterbrook P, Ressler S, Yang F, Rowley D, Vyakarnam A. WFDC1/ps20 is a novel innate immunomodulatory signature protein of HIV permissive memory CD4 T-cells that promotes infection by up-regulating CD54 integrin expression and is elevated in HIV-1 infection. J Virol 2008, 82:471-486. 10.1128/JVI.00939-07, 2224370, 17942534.
30. Bingle CD, Vyakarnam A. Novel innate immune functions of the whey acidic protein family. Trends Immunol 2008, 29:444-453. 10.1016/j.it.2008.07.001, 18676177.
31. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, Ding A, Knowles DM, Santini PA, Cerutti A. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol 2007, 8:294-303. 10.1038/ni1434, 17259987.
32. Conticello SG, Langlois MA, Yang Z, Neuberger MS. DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv Immunol 2007, 94:37-73. full_text, 17560271.
33. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, Asher AI, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009, 199:1177-1185. 10.1086/597476, 2728622, 19265479.
34. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE 2008, 3:e2516. 10.1371/journal.pone.0002516, 2424175, 18575590.
35. Reddy S, Vyakarnam A. Conference on Retroviruses and Opportunistic Infections; San Francisco 2010,
36. Yamamoto JK, Barre-Sinoussi F, Bolton V, Pedersen NC, Gardner MB. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III and ARV-2. J Interferon Res 1986, 6:143-152.
37. Pitha PM. Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res 1994, 24:209-215.
38. Tough DF. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 2004, 45:257-264. 10.1080/1042819031000149368, 15101709.
39. Takeuchi H, Matano T. Host factors involved in resistance to retroviral infection. Microbiol Immunol 2008, 52:318-325. 10.1111/j.1348-0421.2008.00040.x, 18577167.
40. Malim MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 2009, 364:675-687. 10.1098/rstb.2008.0185, 2660912, 19038776.
41. Towers GJ. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 2007, 4:40. 10.1186/1742-4690-4-40, 1906832, 17565686.
42. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430. 10.1038/nature06553, 18200009.
43. Malim MH, Emerman M. HIV-1 accessory proteins - ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3:388-398. 10.1016/j.chom.2008.04.008, 18541215.
44. Neil SJ, Bieniasz PD. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 2009, 29:569-580. 10.1089/jir.2009.0077, 19694548.
45. Asaoka K, Ikeda K, Hishinuma T, Horie-Inoue K, Takeda S, Inoue S. A retrovirus restriction factor TRIM5alpha is transcriptionally regulated by interferons. Biochem Biophys Res Commun 2005, 338:1950-1956. 10.1016/j.bbrc.2005.10.173, 16289103.
46. Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006, 80:7645-7657. 10.1128/JVI.00206-06, 1563726, 16840343.
47. Peng G, Le I, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 2006, 203:41-46. 10.1084/jem.20051512, 2118075, 16418394.
48. Sakuma R, Mael AA, Ikeda Y. Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J Virol 2007, 81:10201-10206. 10.1128/JVI.00419-07, 2045407, 17609277.
49. Neil SJ, S V, S WI, Bieniasz PD. An interferon alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007, 2:193-203. 10.1016/j.chom.2007.08.001, 18005734.
50. Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, Orenstein JM, Dieffenbach CW, Friedman RM, Meltzer MS. Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol 1990, 145:2669-2676.
51. Gendelman HE, Friedman RM, Joe S, Baca LM, Turpin JA, Dveksler G, Meltzer MS, Dieffenbach C. A selective defect of interferon alpha production in human immunodeficiency virus-infected monocytes. J Exp Med 1990, 172:1433-1442. 10.1084/jem.172.5.1433, 2188659, 2264889.
52. Tsang J, Chain BM, Miller RF, Webb BL, Barclay W, Towers GJ, Katz DR, Noursadeghi M. HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation. AIDS 2009, 23:2255-2263. 10.1097/QAD.0b013e328331a4ce, 2873676, 19741482.
53. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale MJ. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 2009, 83:10395-10405. 10.1128/JVI.00849-09, 2753137, 19706707.
54. Wang Y, Bergmeier LA, Stebbings R, Seidl T, Whittall T, Singh M, Berry N, Almond N, Lehner T. Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4+ memory T cells. Vaccine 2009, 27:870-881. 10.1016/j.vaccine.2008.11.084, 2744409, 19084567.
55. Turelli P, Liagre-Quazzola A, Mangeat B, Verp S, Jost S, Trono D. APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice. J Virol 2008, 82:6585-6590. 10.1128/JVI.00216-08, 2447049, 18434399.
56. Hirbod T, Bailey RC, Agot K, Moses S, Ndinya-Achola J, Murugu R, Andersson J, Nilsson J, Broliden K. Abundant expression of HIV target cells and C-type lectin receptors in the foreskin tissue of young Kenyan men. Am J Pathol 2010, 176:2798-2805. 10.2353/ajpath.2010.090926, 20395432.
57. Hodges A, Sharrocks K, Edelmann M, Baban D, Moris A, Schwartz O, Drakesmith H, Davies K, Kessler B, McMichael A, Simmons A. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol 2007, 8:569-577. 10.1038/ni1470, 17496896.
58. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TB. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 2010, 11:419-426. 10.1038/ni.1858, 20364151.
59. Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Geijtenbeek TBH. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol 2009, 10:1081-1088. 10.1038/ni.1778, 19718030.
60. de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T, Piguet V, van Kooyk Y, Geijtenbeek TB. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med 2007, 13:367-371. 10.1038/nm1541, 17334373.
61. Fahrbach KM, Barry SM, Ayehunie S, Lamore S, Klausner M, Hope TJ. Activated CD34-derived Langerhans cells mediate transinfection with human immunodeficiency virus. J Virol 2007, 81:6858-6868. 10.1128/JVI.02472-06, 1933306, 17442711.
62. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, Geijtenbeek TB, Gallay P. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci USA 2007, 104:19464-19469. 10.1073/pnas.0703747104, 2148312, 18040049.
63. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009, 458:1034-1038. 10.1038/nature07831, 2785041, 19262509.
64. Cameron PU, Handley AJ, Baylis DC, Solomon AE, Bernard N, Purcell DF, Lewin SR. Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes. J Virol 2007, 81:2297-2306. 10.1128/JVI.01795-06, 1865918, 17166903.
65. Pion M, Granelli-Piperno A, Mangeat B, Stalder R, Correa R, Steinman RM, Piguet V. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med 2006, 203:2887-2893. 10.1084/jem.20061519, 2118170, 17145955.
66. Loré K, Smed-Sörensen A, Vasudevan J, Mascola JR, Koup RA. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med 2005, 201:2023-2033. 10.1084/jem.20042413, 2212038, 15967828.
67. Groot F, van Capel TM, Kapsenberg ML, Berkhout B, de Jong EC. Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition. Blood 2006, 108:1957-1964. 10.1182/blood-2006-03-010918, 16705088.
68. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG, Larsson M, Gorelick RJ, Lifson JD, Bhardwaj N. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005, 115:3265-3275. 10.1172/JCI26032, 1253628, 16224540.
69. Meier A, Alter G, Frahm N, Sidhu H, Li B, Bagchi A, Teigen N, Streeck H, Stellbrink HJ, Hellman J, et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol 2007, 81:8180-8191. 10.1128/JVI.00421-07, 1951290, 17507480.
70. Fonteneau JF, Larsson M, Beignon AS, McKenna K, Dasilva I, Amara A, Liu YJ, Lifson JD, Littman DR, Bhardwaj N. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 2004, 78:5223-5232. 10.1128/JVI.78.10.5223-5232.2004, 400371, 15113904.
71. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009, 83:3719-3733. 10.1128/JVI.01844-08, 2663284, 19176632.
72. Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, Meyer L, Oksenhendler E, Sinet M, Hosmalin A. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001, 98:3016-3021. 10.1182/blood.V98.10.3016, 11698285.
73. Malleret B, Manéglier B, Karlsson I, Lebon P, Nascimbeni M, Perié L, Brochard P, Delache B, Calvo J, Andrieu T, et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 2008, 112:4598-4608. 10.1182/blood-2008-06-162651, 18787223.
74. Brown KN, Wijewardana V, Liu X, Barratt-Boyes SM. Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathog 2009, 5:e1000413. 10.1371/journal.ppat.1000413, 2671605, 19424421.
75. Loré K, Sönnerborg A, Broström C, Goh LE, Perrin L, McDade H, Stellbrink HJ, Gazzard B, Weber R, Napolitano LA, et al. Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS 2002, 16:683-692. 10.1097/00002030-200203290-00003, 11964524.
76. Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008, 47:385-395. 10.1002/hep.21996, 18064579.
77. Liang H, Russell RS, Yonkers NL, McDonald D, Rodriguez B, Harding CV, Anthony DD. Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J Virol 2009, 83:5693-5707. 10.1128/JVI.02671-08, 2681964, 19297478.
78. Herbeuval JP, Hardy AW, Boasso A, Anderson SA, Dolan MJ, Dy M, Shearer GM. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type 1 IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2005, 102:13974-13979. 10.1073/pnas.0505251102, 1224361, 16174727.
79. Mueller YM, Do DH, Altork SR, Artlett CM, Gracely EJ, Katsetos CD, Legido A, Villinger F, Altman JD, Brown CR, et al. IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses. J Immunol 2008, 180:350-360. 2929904, 18097036.
80. Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF, Lindsay RJ, Orellana L, Mildvan D, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009, 15:955-959. 10.1038/nm.2004, 2821111, 19597505.
81. Estes JD, Gordon SN, Zeng M, Chahroudi AM, Dunham RM, Staprans SI, Reilly CS, Silvestri G, Haase AT. Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol 2008, 180:6798-6807. 2596686, 18453600.
82. Diop OM, Ploquin MJ, Mortara L, Faye A, Jacquelin B, Kunkel D, Lebon P, Butor C, Hosmalin A, Barré-Sinoussi F, Müller-Trutwin MC. Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome. J Virol 2008, 82:5145-5152. 10.1128/JVI.02433-07, 2395206, 18385227.
83. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, Francella N, Sidahmed A, Smith AJ, Cramer EM, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009, 119:3556-3572. 2786806, 19959874.
84. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Silvestri G, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009, 119:3544-3555. 2786805, 19959873.
85. Lederer S, Favre D, Walters KA, Proll S, Kanwar B, Kasakow Z, Baskin CR, Palermo R, McCune JM, Katze MG. Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog 2009, 5:e1000296. 10.1371/journal.ppat.1000296, 2633618, 19214219.
86. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990, 322:166-172. 10.1056/NEJM199001183220305, 1967191.
87. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, Hamann D, Prins M, Miedema F. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003, 17:1881-1888. 10.1097/00002030-200309050-00006, 12960820.
88. Durudas A, Milush JM, Chen HL, Engram JC, Silvestri G, Sodora DL. Elevated levels of innate immune modulators in lymph nodes and blood are associated with more-rapid disease progression in simian immunodeficiency virus-infected monkeys. J Virol 2009, 83:12229-12240. 10.1128/JVI.01311-09, 2786739, 19759147.
89. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC, Diemand S, Honda K, Kundig TM, Aguzzi A, Speck RF. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 2009, 113:377-388. 10.1182/blood-2008-04-151712, 18824599.
90. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Mucking S, Barrat FJ, Coffman RL, Staprans SI, Feinberg MB. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008, 14:1077-1087. 10.1038/nm.1871, 18806803.
91. Campillo-Gimenez L, Laforge M, Fay M, Brussel A, Cumont MC, Monceaux V, Diop O, Lévy Y, Hurtrel B, Zaunders J, et al. Nonpathogenesis of simian immunodeficiency virus infection is associated with reduced inflammation and recruitment of plasmacytoid dendritic cells to lymph nodes, not to lack of an interferon type I response, during the acute phase. J Virol 2010, 84:1838-1846. 10.1128/JVI.01496-09, 2812402, 19939930.
92. Kornfeld C, Ploquin MJ, Pandrea I, Faye A, Onanga R, Apetrei C, Poaty-Mavoungou V, Rouquet P, Estaquier J, Mortara L, et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 2005, 115:1082-1091. 1062895, 15761496.
93. Kirchoff F. Is the high virulence of HIV-1 an unfortunate coincidence of primate lentiviral evolution?. Nat Rev Microbiol 2009, 7:467-476.
94. Granelli-Piperno A, Golebiowska A, Trumpfheller C, Siegal FP, Steinman RM. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc Natl Acad Sci USA 2004, 101:7669-7674. 10.1073/pnas.0402431101, 419664, 15128934.
95. Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D, Shearer GM. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 2007, 109:3351-3359. 10.1182/blood-2006-07-034785, 1852248, 17158233.
96. Manches O, Munn D, Fallahi A, Lifson J, Chaperot L, Plumas J, Bhardwaj N. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest 2008, 118:3431-3439. 10.1172/JCI34823, 2528911, 18776940.
97. Alter G, Teigen N, Ahern R, Streeck H, Meier A, Rosenberg ES, Altfeld M. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007, 195:1452-1460. 10.1086/513878, 17436225.
98. Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg ES, Miller JS, Carrington M, Altfeld M. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009, 83:6798-6805. 10.1128/JVI.00256-09, 2698561, 19386717.
99. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999, 10:661-671. 10.1016/S1074-7613(00)80065-5, 10403641.
100. Bonaparte MI, Barker E. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility class I molecules. Blood 2004, 104:2087-2094. 10.1182/blood-2004-02-0696, 15117765.
101. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, Streeck H, Waring M, Meier A, Brander C, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007, 204:3027-3036. 10.1084/jem.20070695, 2118524, 18025129.
102. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, Trowsdale J, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002, 31:429-434.
103. Qi Y, Martin MP, Gao X, Jacobson L, Goedert JJ, Buchbinder S, Kirk GD, O'Brien SJ, Trowsdale J, Carrington M. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathogens 2006, 2:741-745.
104. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S, Brown EE, Shupert WL, Phair J, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007, 39:733-740. 10.1038/ng2035, 17496894.
105. Bostik P, Kobkitjaroen J, Tang W, Villinger F, Pereira L, Little DM, Stephenson ST, Bouzyk M, Ansari AA. Decreased NK cell frequency and function is associated with increased risk of KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhesus macaques with high viral loads. J Immunol 2009, 182:3638-3649. 10.4049/jimmunol.0803580, 19265142.
106. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, Theodorou I, Barre-Sinoussi F, Pancino G. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003, 171:5663-5667.
107. Montoya CJ, Velilla PA, Chougnet C, Landay AL, Rugeles MT. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006, 120:138-146. 10.1016/j.clim.2006.02.008, 16624619.
108. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, Nguyen N, Truong LX, Theodorou I, Barre-Sinoussi F, Pancino G, Paul P. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007, 109:4296-4305. 10.1182/blood-2006-08-040238, 17272507.
109. Boulet S, Sharafi S, Simic N, Bruneau J, Routy JP, Tsoukas CM, Bernard NF. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008, 22:595-599. 10.1097/QAD.0b013e3282f56b23, 18317000.
110. Boulet S, Song R, Kamya P, Bruneau J, Shoukry NH, Tsoukas CM, Bernard NF. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J Immunol 2010, 184:2057-2064. 10.4049/jimmunol.0902621, 20061407.
111. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 2009, 31:15-23. 10.1016/j.immuni.2009.06.008, 19604490.
112. Fausther-Bovendo H, Sol-Foulon N, Candotti D, Agut H, Schwartz O, Debre P, Vielliard V. HIV escape from natural killer cell cytotoxicity: nef inhibits NKp44L expression on CD4+ T cells. AIDS 2009, 23:1077-1087. 10.1097/QAD.0b013e32832cb26b, 19424050.
113. Gaudieri S, DeSantis D, McKinnon E, Moore C, Nolan D, Witt CS, Mallal SA, Christiansen FT. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 2005, 6:683-690.
114. Long BR, Ndhlovu LC, Oksenberg JR, Lanier LL, Hecht FM, Nixon DF, Barbour JD. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol 2008, 82:4785-4792. 10.1128/JVI.02449-07, 2346752, 18305035.
115. Vieillard V, Le Grand R, Dausset J, Debre P. A vaccine strategy against AIDS: an HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques. Proc Natl Acad Sci USA 2008, 105:2100-2104. 10.1073/pnas.0711629105, 2542869, 18234855.
116. Fernandez CS, Chan AC, Kyparissoudis K, De Rose R, Godfrey DI, Kent SJ. Peripheral NKT cells in simian immunodeficiency virus-infected macaques. J Virol 2009, 83:1617-1624. 10.1128/JVI.02138-08, 2643790, 19052081.
117. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104. 10.1038/nature06106, 17805298.
118. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007, 178:6596-6603.
119. Kared H, Lelièvre JD, Donkova-Petrini V, Aouba A, Melica G, Balbo M, Weiss L, Lévy Y. HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection. AIDS 2008, 22:2451-2460. 10.1097/QAD.0b013e328319edc0, 19005268.
120. O'Leary JG, Goodarzi M, Drayton DL, von Andrian UH. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol 2006, 7:507-516. 10.1038/ni1332, 16617337.
121. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561. 10.1038/nature07665, 2674434, 19136945.
122. Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci USA 2009, 106:1915-1919. 10.1073/pnas.0813192106, 2644138, 19181844.
123. Cummins JEJ, Doncel GF. Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex Transm Dis 2009, 36:S84-91. 10.1097/OLQ.0b013e3181994191, 19218890.